Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.
about
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.Emerging agents for the treatment of mantle cell lymphoma.Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group.Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.How to manage mantle cell lymphoma.Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma
P2860
Q33394153-369D9A58-7001-4DD2-976B-9797990C986AQ33396261-417BD3D3-9796-4506-9628-9A062B6607D4Q33415901-E4315D95-F4F0-4936-8D13-DB309919A8C8Q33425005-DD10734B-4693-498B-953C-E7269FC21EDBQ33890300-45F06E13-130B-4052-A9DC-406DE6E8BAC1Q36889248-398CF0AD-9B51-47E1-A81D-F04D516BBF7EQ38055498-684AE3C5-7D5B-4CC6-9391-A9077D69FF25Q38110232-6F34E12C-CCCC-470A-BAF6-47D48AC302A7Q38122437-97BAC51B-A827-4DEB-B31D-249586A4EC41Q38768797-3247AA36-58F4-47A8-88B9-DD7C872CA17BQ39187610-670104E3-C25F-4280-8336-32D47F868CDBQ41674989-333720A3-3F67-4DD3-8FB5-CA9BA22251B4Q46060588-51A584FE-60DD-4821-8AEE-D71D87025C01Q46909218-0918B14D-BA46-4DF9-B8B0-70673650CDBFQ53153689-DE639CC6-D8A4-4FDB-A467-3B229CDFEADAQ56882990-0DC175EB-B02E-498D-B3F2-399E2D269D60
P2860
Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@ast
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@en
type
label
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@ast
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@en
prefLabel
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@ast
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@en
P2093
P356
P1433
P1476
Phase II study of gemcitabine- ...... fractory mantle cell lymphoma.
@en
P2093
B Coiffier
C Dumontet
F Morschhauser
M Wetterwald
P Solal-Céligny
P304
P356
10.1093/ANNONC/MDL395
P577
2006-10-30T00:00:00Z